

RESEARCH ARTICLE

Open Access



The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function

Anne-Marie Gabrielsen^{1,2}, Torbjørn Omland^{3,4}, Mette Brokner⁵, Jan Magnus Fredheim¹, Jens Jordan⁶, Sverre Lehmann^{7,10}, May Brit Lund⁸, Jøran Hjelmæsæth^{1,9*} and Dag Hofsvø¹

Abstract

Background: Obesity is a major risk factor for obstructive sleep apnea, impaired pulmonary function and heart failure, but obesity is also associated with paradoxically low levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP). In subjects with severe obesity undergoing weight loss treatment, we assessed the associations between changes in severity of obstructive sleep apnea, pulmonary function and serum NT-proBNP levels.

Methods: One-year non-randomized controlled clinical trial. Participants, 69.6 % women, mean (SD) age 44.6 (10.8) years and body mass index (BMI) 45.1 (5.6) kg/m², underwent gastric bypass surgery (n = 76) or intensive lifestyle intervention (n = 63), resulting in 30 (8) % and 8 (9) % weight loss, respectively. The reference group included 30 normal weight, healthy, gender and age matched controls. Sleep recordings, arterial blood gases, pulmonary function and blood tests were assessed before and 1 year after the interventions.

Results: NT-proBNP concentrations increased significantly more after surgery than after lifestyle intervention. The post intervention values in both groups were significantly higher than in a normal weight healthy reference group. In the whole study population changes (Δ) in NT-proBNP correlated significantly with changes in both BMI ($r = -0.213$) and apnea hypopnea index (AHI, $r = -0.354$). Δ NT-proBNP was, independent of age, gender and Δ BMI, associated with Δ AHI (beta -0.216 , $p = 0.021$). Δ AHI was, independent of Δ BMI, significantly associated with changes in pO_2 (beta -0.204), pCO_2 (beta 0.199), forced vital capacity (beta -0.168) and forced expiratory volume first second (beta -0.160).

Conclusions: Gastric bypass surgery was associated with a greater increase in NT-proBNP concentrations than non-surgical weight loss treatment. Reduced AHI was, independent of weight loss, associated with increased NT-proBNP levels and improved dynamic lung volumes and daytime blood gases.

Clinical Trial Registration ClinicalTrials.gov NCT00273104, retrospectively registered Jan 5, 2006 (study start Dec 2005)

Keywords: Obesity, Natriuretic peptides, Sleep apnea, Respiration

Background

Obesity is a major risk factor for obstructive sleep apnea (OSA), impaired pulmonary function and heart failure

[1–4]. Fat deposits narrow upper airways while abdominal fat masses decrease tracheal tension, thus, increasing upper airway collapsibility [5]. Obesity also restricts diaphragm movement and causes alveolar and airway closure at the lung base, thus perturbing respiratory physiology and blood gases [6–8]. Increased heart failure risk may be mediated through obesity-associated arterial hypertension, volume expansion, dyslipidemia,

*Correspondence: joran.hjelmæsæth@siv.no

¹ Morbid Obesity Center, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Full list of author information is available at the end of the article

and insulin resistance [9, 10]. The presence of OSA and impaired pulmonary function may further exacerbate cardiovascular risk and symptom burden.

ProBNP produced in ventricular cardiomyocytes is processed to the N-terminal peptide (NT-proBNP) and biologically active BNP. Circulating BNP and NT-proBNP levels are established heart failure biomarkers [11–13]. In spite of the cardiac overload, circulating NT-proBNP/BNP concentrations are paradoxically reduced in obesity [14, 15], and increase following either weight loss induced by bariatric surgery [16, 17] or intensive lifestyle intervention [18]. Impaired natriuretic peptide release and increased degradation of BNP through adipose natriuretic peptide clearance receptors [19] and neprilysin [20] have been reported. Moreover, adipose natriuretic peptide clearance receptor expression decreases with weight loss [21]. Although NT-proBNP is not cleared by NPR-C receptors or neprilysin, there is still an inverse association between body mass index (BMI) and NT-proBNP [15]. Natriuretic peptides counteract cardiac overload through natriuresis and vasodilatation. They also augment lipid mobilization and muscular oxidative capacity, thereby ameliorating obesity-associated metabolic disease [22–28]. Finally, natriuretic peptide receptors are expressed in the lung, and natriuretic peptide infusion elicits bronchial dilatation [29]. While relative natriuretic peptide deficiency could link cardiometabolic and pulmonary disease in obesity, data concerning the associations between OSA severity and pulmonary function, blood gases and NT-proBNP is scarce [30].

We have previously shown that improvements in obstructive sleep apnea [5], pulmonary function and blood gases [31], and obesity related cardiovascular risk factors [32, 33] in subjects with morbid obesity following surgical and non-surgical weight loss are mediated through weight loss and not by the surgical procedure per se. This ancillary study assesses the impact of surgical and non-surgical weight-loss, obstructive sleep apnea, and pulmonary function on circulating NT-proBNP. Given the hemodynamic stress imposed by OSA and pulmonary disease, we hypothesized that improvement in OSA and pulmonary function would counterbalance the expected increase in NT-proBNP during weight loss. Furthermore, we assessed the associations between apnea hypopnea index (AHI) and pulmonary function during weight loss.

Methods

Subjects and intervention

The MOBIL study (ClinicalTrials.gov identifier NCT00273104) was conducted at Vestfold Hospital Trust, Norway, between December 2005 and June 2009. Patients in the surgery group underwent laparoscopic

Roux-en-Y gastric bypass surgery and were examined by a surgeon after 6 weeks and assessed by a dietician quarterly. Moreover, the subjects in both treatment groups were seen by an internist every half a year, in addition to a dietician when required. The subjects in the lifestyle group were referred to a rehabilitation center (Evdjektivlinikken) specializing in the care of morbid obesity. The 1-year lifestyle program aimed to induce a weight loss of at least 10 %, and composed of four stays at the center, with a total of a 7 weeks stay. The daily program was divided between physical activity (3–4 h) and different psychosocial interventions involving a medical doctor, a nutritionist, a physiotherapist and a trained nurse. Details concerning the interventions have been published previously [32]. For analyses of NT-proBNP the subjects with morbid obesity were compared with a reference group of 30 normal weight controls (67 % female), mean BMI (SD) 22.7 (1.5) kg/m², mean age (SD) 42.6 (8.5) years, recruited among employees at Vestfold Hospital Trust.

Examinations and definitions

Daytime arterial blood gases, pulmonary function tests, sleep registrations and blood samples were carried out at baseline and 1 year after intervention. All subjects were examined by a physician. Weight, height, medical history, including smoking (pack/years), medications and electrocardiograms were recorded [31]. Asthma was defined as physician-diagnosed asthma, and chronic obstructive pulmonary disease was defined as forced expiratory volume first second (FEV1)/forced vital capacity (FVC) <0.7 [34].

Sleep recordings

Sleep recordings were performed using Embletta™; a nine channel portable somnograph including pulse oximetry. An apnea was defined as a 90 % or more reduction in baseline nasal airflow lasting at least 10 s. A hypopnea was defined as a 50–90 % reduction in pre-event nasal airflow lasting ≥ 10 s accompanied by at least a 3 % drop in oxygen saturation. AHI was defined as the total number of apneas and hypopneas (events) per hour. Oxygen desaturation index was defined as the number oxygen desaturations (≥ 3 % drop) per hour. Obstructive sleep apnea (OSA) was defined as being ≥ 5 events per hour during sleep. OSA was categorized into mild (AHI 5 to <15 events/hour), moderate (AHI 15 to <30 events/hour) and severe (AHI ≥ 30 events/hour) [5]. Scoring rules were in accordance with the 2007 American Academy of Sleep Medicine manual for scoring sleep [35]. To assess the effect of moderate/severe OSA in this study, we dichotomized the subjects into high AHI (≥ 15 events/hour) and low AHI (<15 events/hour).

Patients with AHI ≥ 15 events/hour, or AHI 5 to <15 events/hour and symptoms of sleep apnoea, were offered a CPAP (Continuous positive airway pressure—Autoset spirit, ResMed), while patients with additional daytime hypercapnia ($\text{PCO}_2 > 6.0$ kPa) were offered a bilevel PAP (VPAP 4, ResMed). These subjects were followed at their outpatient clinics.

Pulmonary function measurements

Pulmonary function measurements included dynamic spirometry, static lung volumes and gas diffusion capacity. These tests were carried out by two experienced nurses according to the guidelines recommended by the ATS-ERS task force [36–38]. Recorded variables were: FVC (forced vital capacity), FEV1 (forced vital capacity the first second first second), FEV1/FVC, TLC (total lung capacity), VC (vital capacity), IC (inspiratory capacity), FRC (functional residual capacity), ERV (expiratory reserve volume), RV (residual volume), DLCO (diffusion capacity of carbon monoxide) and DLCO/VA (DLCO/alveolar volume). The Jaeger Master Lab (Eric Jaeger, Wurzburg, Germany) was used in all tests and calibrated daily using a 1 l syringe. The reference values were those recommended by the European Respiratory Society (ERS) [39]. However, since the ERS offers no reference values for ERV, the Jaeger Master Lab reference values were used instead. All tests were carried out between 9 am and 10 am with the subjects sitting in an upright position wearing a nose clip. No anti-obstructive medication was allowed prior to pulmonary function testing.

Blood gas analyses

Arterial blood for the analysis of gases during room air breathing was drawn in all patients from the radial artery after a 5-min rest period. Arterial puncture was performed by either a physician (AMG) or two experienced nurses. For analyses we used an ABL 735 Radiometer (Copenhagen, Denmark) calibrated in accordance with the manufacturer's specifications.

Blood samples

Venous blood samples were collected after overnight fasting, clotted for 30 min at room temperature, and serum was separated by centrifugation. Samples were either analyzed immediately or stored at -80 °C until analysis [32]. NT-proBNP was analyzed by an immunometric assay on Vitros 5600 (Ortho-Clinical Diagnostics, NJ, USA), using calibrators and reagents from Ortho-Clinical Diagnostics according to the manufacturer's instructions. Serum from the reference group had not been thawed previously. By contrast, 47 % of the baseline serum samples from the morbidly obese population had been thawed once, 5 % had been thawed two or three times, and 48 % had never

been thawed. The frequency of freeze-thaw cycles did not differ significantly between the AHI groups or the intervention groups. The coefficient of variation was 8 %.

Statistical analyses

Data are presented as mean (SD) or number (%) unless otherwise specified. Between-group comparisons were analyzed using independent samples *t* test, Mann–Whitney U test or multiple linear regression analysis for continuous variables and Fisher's exact test for categorical variables. Within-group comparisons were performed using paired samples *t* test for continuous variables. The effect size and statistical significance of the uni- and multivariate associations were evaluated using Pearson's correlation and linear regression analyses. NT-proBNP had a skewed distribution and the values were therefore transformed to approximate normal distribution using natural logarithms (ln-transformation). NT-proBNP values were missing in three subjects due to shortage of serum, and one subject had missing AHI value due to non-compliance. In addition, three subjects had predicted mean Δ NT-proBNP values >3 SD from mean and were excluded from the analyses (two of these subjects developed heart failure during the intervention period). The significance level was set at 0.05. Statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL).

Results

A total of 76 subjects underwent laparoscopic Roux-en-Y gastric bypass surgery, [53 (70 %) female, mean (SD) age 43 (11) years, mean (SD) BMI 46.7 (5.7) kg/m^2], while 63 subjects attended an intensive lifestyle intervention program, [44 (70 %) women, mean (SD) age 47 (11) years, mean (SD) BMI 43.4 (5.0) kg/m^2]. Mean (SD) weight reduction was 30 (8) % in the surgery group and 8 (9) % in the lifestyle group [32] with post intervention BMIs of 32.6 (5.2) and 39.6 (5.6) kg/m^2 , respectively ($p < 0.001$).

NT-proBNP—association with surgical and non-surgical weight loss

At baseline, women had significantly higher NT-proBNP levels than men [median (25–75 percentiles) 7.4 (5.2–12.3) pmol/l versus 5.1 (3.4–8.3) pmol/l, $p = 0.004$]. Moreover, NT-proBNP correlated significantly with age ($r = 0.196$, $p = 0.024$), but not with pack years ($r = 0.002$, $p = 0.980$). NT-proBNP at baseline did not differ between those who had gastric bypass surgery ($n = 71$) or those who were treated with intensive lifestyle intervention ($n = 62$, Fig. 1).

NT-proBNP increased significantly after both interventions, but significantly more in the surgery group (Fig. 1). The post intervention values were significantly higher in the surgery and lifestyle groups than the in the reference




Fig. 1 Median NT-proBNP-levels (25–75 percentiles) at baseline and after gastric bypass surgery (n = 71) and lifestyle intervention (n = 62). p values indicate significant changes within and between the intervention groups. The grey background represents the 25–75 percentile for the NT-proBNP levels in the normal weight healthy reference group (n = 30)




Fig. 2 Scatter plot demonstrating the correlations between changes in NT-proBNP and changes in BMI after gastric bypass surgery and intensive lifestyle intervention

group ($p < 0.001$, $p = 0.010$, respectively). In addition, there was a negative correlation between changes in BMI and NT-proBNP (Fig. 2) and this correlation was independent of type of intervention (no “group x Δ NT-proBNP” interaction, $p = 0.409$).

NT-proBNP at baseline—association with AHI and pulmonary function

Baseline characteristics and comorbidities of the low and high AHI groups are shown in Table 1 and Additional file 1: Table S1. In the low AHI group subjects were younger than in the high AHI group, while the mean BMI was lower and the proportion of females was higher. Four subjects (10 %) with high AHI had five or more central apneas during the night, whereas none with low AHI had central apneas ($p = 0.008$).

No significant difference in NT-proBNP levels at baseline between the low and high AHI groups were observed (Fig. 3). NT-proBNP correlated significantly and positively with both FRC ($r = 0.329$, $p < 0.001$) and RV ($r = 0.215$, $p = 0.017$), but not with other static or dynamic lung volumes, measures of diffusing capacity or blood gas values. The associations between NT-proBNP and FRC (Beta = 0.296, $p = 0.002$), but not RV (Beta = 0.152, $p = 0.112$), persisted after adjusting for pack years, gender, age and BMI.

NT-proBNP during weight loss—association with changes in AHI and pulmonary function

Δ AHI varied considerably (range -75 to 30 events/hour) and was negatively and significantly associated with Δ NT-proBNP (Fig. 4). This association

persisted after adjusting for age, gender and Δ BMI (beta = -0.216 , $p = 0.021$). In this model, the association between Δ BMI and Δ NT-proBNP observed in the univariate analyses was no longer significant (beta -0.130 , $p = 0.156$). There was no significant interaction between treatment group and Δ AHI ($p = 0.056$). Δ NT-proBNP correlated significantly with Δ DLCO/VA ($r = -0.185$, $p = 0.034$), Δ IC ($r = -0.225$, $p = 0.013$) and Δ ERV ($r = 0.243$, $p = 0.007$). However, after adjustments for age, gender, pack years and Δ BMI, these associations were attenuated and no longer significantly associated with Δ NT-proBNP.

Pulmonary function—association with AHI at baseline and during weight loss



Hypercapnia and hypoxemia were observed in the high AHI group (Table 1). With the exception of a significantly higher TLC in the low AHI group, no differences in static and dynamic lung volumes or measures of diffusing capacity were observed. After adjustments for age, gender, pack years and baseline BMI, only pO_2 remained significantly higher in subjects with AHI < 15 than in those with AHI ≥ 15 ($p = 0.035$).

Univariate linear regression analyses showed that Δ AHI were negatively associated with changes in pO_2 , FVC, FEV1, VC and ERV and positively associated with changes in pCO_2 (Additional file 1: Table S2). After multiple adjustments, the associations between Δ AHI and changes in pO_2 , pCO_2 , FVC and FEV1 were attenuated, but remained significant. Although statistically significant, the effect sizes were small and explained one to four percent of the variation (squared partial correlation) in these variables. By contrast, the associations between weight loss (Δ BMI) and dynamic lung volumes were large, explaining 25 % of the variation in both Δ FVC and Δ FEV1. No interactions with Δ BMI were found for any of these variables.

Table 1 Baseline characteristics according to AHI level

Variable	Low AHI (<15 events/hour)	High AHI (≥ 15 events/hour)	p
Number (n)	96	42	
Female gender (%)	76 (79)	20 (48)	<0.001
Age (years)	43.0 (11.1)	48.2 (9.4)	0.009
BMI (kg/m ²)	44.4 (5.0)	46.8 (6.6)	0.022
Surgical treatment (%)	50 (52)	26 (62)	0.353
Arterial blood gases			
pO ₂ (kPa)	11.8 (1.3)	10.7 (1.4)	<0.001
pCO ₂ (kPa)	5.1 (0.5)	5.5 (0.5)	0.001
Diffusing capacity			
DLCO (diffusing capacity for carbon monoxide) (% pred)	93 (13)	92 (17)	0.752
DLCO/VA (diffusing capacity for CO/alveolar volume) (% pred)	106 (15)	111 (19)	0.135
Dynamic lung volumes			
FVC (forced vital capacity) (% pred)	104 (14)	98 (16)	0.055
FEV1 (forced vital capacity first second) (% pred)	94 (15)	93 (20)	0.680
Static lung volumes			
TLC (total lung capacity) (% pred)	100 (13)	94 (13)	0.033
IC (inspiratory capacity) (% pred)	123 (22)	115 (25)	0.098
VC (vital capacity) (% pred)	100 (15)	96 (18)	0.136
FRC (functional residual capacity) (% pred)	82 (17)	79 (16)	0.315
ERV (expiratory reserve volume) (% pred)	48 (35)	49 (34)	0.885
RV (residual volume) (% pred)	101 (28)	97 (27)	0.493

Data are presented as mean (SD), or n (%), as appropriate



Discussion

This study has three key findings. First, NT-proBNP values rose significantly more after gastric bypass surgery than after lifestyle intervention, and the post intervention NT-proBNP values in both groups were significantly higher than in a normal weight reference group. Second, enhanced NT-proBNP levels correlated with weight loss

and reduction in AHI. Third, the results did not confirm our hypotheses that improved pulmonary function and improvement of OSA might counterbalance NT-proBNP-increase during weight loss.

In addition, reduced AHI was, independent of weight loss, associated with improved dynamic lung volumes and daytime blood gases. Together, these findings suggest that perturbed BNP release, indicated by low circulating

NT-proBNP, could provide a common mechanism linking cardiometabolic disease and OSA in morbid obesity. Moreover, the study may have implications for the use of NT-proBNP as a clinical biomarker in such patients.

NT-proBNP—associations with weight loss and AHI

Given the known obesity-associated increase in cardiac volume loading and left ventricular mass, the low to normal NT-proBNP values observed in morbid obesity in both the present study and previous studies [14, 15, 40] are unexpected. In fact, and in line with our finding, NT-proBNP increases after weight reduction induced by either gastric bypass [16, 17] or lifestyle interventions [18], while the heart is unloaded. In our study, patients following weight loss, while remaining overweight-obese, nevertheless exhibited higher NT-proBNP values compared to a normal weight reference group. This hitherto unknown phenomenon suggests that weight loss may unmask cardiac strain-induced BNP release. It is also possible that glomerular hyperfiltration which is associated with obesity [41, 42] may result in lower concentrations of NT-proBNP in obese patients. Weight loss also affects natriuretic peptide clearance mechanisms [21] such that systemic BNP availability is expected to increase further. These findings may indicate that the presence of obesity may disable BNP release, which could be regarded as safeguard against excess cardiac loading.

The association between sleep apnea and heart failure is well documented [43, 44]. NT-proBNP levels might therefore be expected to be particularly high in patients with OSA. However, our findings showed NT-proBNP levels to not be significantly higher in subjects with OSA than in subjects without OSA. Partly contrasting this finding, we found a negative association between changes in NT-proBNP and changes in AHI. The association remained after adjustments for changes in BMI. In partial agreement with this finding, an inverse association between obstructive sleep apnea severity and NT-proBNP levels was observed in a study of 1655 community-dwelling participants [45]. However, and in contrast to our findings, this association was markedly attenuated after adjustments for BMI. Furthermore, several other studies have reported conflicting data. In a community-based study of 349 Swedish women, a positive dose-relationship between the severity of AHI index and morning BNP level was found [46], and these findings were in line with an earlier, smaller study [47]. In a study of 64 patients with heart failure, no relationship between elevated BNP levels and frequency of sleep apnea was observed [48]. In another study including both patients with heart failure and healthy subjects, no associations between BNP levels and sleep apnoea severity were reported in either group [49].

To sum up, our findings did not support our hypothesis that reduced AHI might counterbalance NT-proBNP-increase during weight loss. Rather the contrary, the increase in NT-proBNP seemed to be more strongly associated with the reduction in AHI than the reduction in BMI.

Pulmonary function—interplay with NT-proBNP and AHI

We have previously shown that improvements in blood gases and pulmonary function after surgical and non-surgical weight loss are mediated through weight loss [31]. The analyses presented in the current paper go further and show significant associations between decreased AHI and improved blood gases as well as dynamic volumes. A decrease in obstructive sleep apnea severity was, independent of weight loss, associated with improvements in arterial pO_2 and pCO_2 as well as an increase in FEV1 and FVC. It has been shown that natriuretic peptide receptors are expressed in the lung, and natriuretic peptide infusion elicits bronchial dilatation [29]. It is tempting to speculate that natriuretic peptides in this way may improve lung function and thereby possibly explain the weight loss independent association between increasing NT-proBNP and decreasing AHI. Importantly, with the exception of a small positive independent association between NT-proBNP and FRC at baseline, we did not find any significant associations between NT-proBNP levels and measures of pulmonary function at baseline or during weight loss supporting this hypothesis.

Strengths and limitations

The strengths of this study include the prospective and comparative design, and the generalizability of the study is relatively high due to the small number of exclusion criteria. The non-randomized design reduces the internal validity of the study. The serum samples were frozen in a biobank for up to 8 years. Although NT-proBNP has been shown to be stable after storage frozen for 2 years and after multiple freeze-thaw cycles [50, 51], we cannot rule out that the higher frequency of freeze-thaw cycles in the morbidly obese population might have resulted in lower NT-proBNP levels than in the reference population. Due to multiple comparisons there is an increased risk of false positive results (type 1 errors). Echocardiography pre and post intervention might have added important information regarding heart function. In addition, the present study lacks compliance data from the CPAP and bilevel machines regarding the use at night. Finally, the study participants were mainly of European origin, meaning that the results cannot automatically be generalized to include other ethnic groups.

Conclusions

In conclusion, weight loss following life style intervention or bariatric surgery reverses BNP deficiency in patients with morbid obesity. This increase could beneficially affect cardiovascular and metabolic disease. More research regarding the beneficial effects of NT-proBNP and BNP in heart failure is thus needed, a position supported by findings from the PARADIGM study which showed improved outcomes in heart failure patients treated with combined angiotensin receptor and neprilysin inhibition [52, 53]. The latter augments systemic natriuretic peptide availability.

In contrast with our hypotheses, the significant improvements in OSA and pulmonary function at follow up did not counterbalance the NT-proBNP-increase during weight loss. Rather the contrary, the increase in NT-proBNP seemed to be more strongly associated with the reduction in AHI than the reduction in BMI. This is difficult to explain, but one might speculate that natriuretic peptides may elicit bronchial dilatation [29] and, accordingly, improve lung function and OSA. However, our findings are clearly hypothesis generating and need further study.

Additional file

Additional file 1. Additional tables.

Abbreviations

BMI: body mass index; NT-proBNP: N-terminal peptide; OSA: obstructive sleep apnea; AHI: apnea hypopnea index; CPAP: continuous positive airway pressure; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide; DLCO/VA: diffusing capacity for carbon monoxide/alveolar volume; TLC: total lung capacity; IC: inspiratory capacity; VC: vital capacity; FRC: functional residual capacity; ERV: expiratory reserve volume; RV: residual volume.

Authors' contributions

AMG, JH, TO and DH planned the study. AMG, JMF and DH organized the study and collected data. AMG and DH performed the statistical analyses. AMG had the major role in writing the manuscript. All authors analyzed and interpreted the data and revised the manuscript critically. All authors read and approved the final manuscript.

Author details

¹ Morbid Obesity Center, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway. ² Department of Internal Medicine, Vestfold Hospital Trust, Tønsberg, Norway. ³ Division of Medicine, Akershus University Hospital, Lørenskog, Norway. ⁴ Institute of Clinical Medicine, Center for Heart Failure Research, University of Oslo, Oslo, Norway. ⁵ Department of Clinical Chemistry, Vestfold Hospital Trust, Tønsberg, Norway. ⁶ Institute for Clinical Pharmacology, University of Hannover, Hanover, Germany. ⁷ Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway. ⁸ Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway. ⁹ Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ¹⁰ Department of Clinical Science, University of Bergen, Bergen, Norway.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Data supporting our findings cannot be shared due to local laws and regulations.

Ethics approval and consent to participate

The study was approved by the regional ethics committee of what was formerly the Southern Norway Regional Health Authority. Written informed consent was provided by all participants.

Funding

This research was funded by the Vestfold Hospital Trust.

Received: 16 April 2016 Accepted: 29 August 2016

Published online: 13 September 2016

References

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser.* 2000;894:1–253.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation.* 2009;120:1640–5.
3. Naimark A, Cherniack RM. Compliance of the respiratory system and its components in health and obesity. *J Appl Physiol.* 1960;15:377–82.
4. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. *Circulation.* 1983;67:968–77.
5. Fredheim JM, Rollheim J, Sandbu R, Hofsvold D, Omland T, Røislien J, et al. Obstructive sleep apnea after weight loss: a clinical trial comparing gastric bypass and intensive lifestyle intervention. *J Clin Sleep Med.* 2013;9:427–32.
6. Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. *Can Respir J.* 2006;13:203–10.
7. Bickelmann AG, Burwell CS, Robin ED, Whaley RD. Extreme obesity associated with alveolar hypoventilation; a Pickwickian syndrome. *Am J Med.* 1956;21:811–8.
8. Kress JP, Pohlman AS, Alverdy J, Hall JB. The impact of morbid obesity on oxygen cost of breathing (VO(2)RESP) at rest. *Am J Respir Crit Care Med.* 1999;160:883–6.
9. Fall T, Hagg S, Magi R, Ploner A, Fischer K, Horikoshi M, et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. *PLoS Med.* 2013;10:e1001474.
10. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. *Physiol Rev.* 2008;88:389–419.
11. Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. *Heart Fail Rev.* 2014;19:453–70.
12. Maisel A, Krishnaswamy P, Nowak R, McCord J, Hollander J, Duc P, et al. Breathing not properly multinational study investigators: rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med.* 2002;347:161–7.
13. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. *Am J Cardiol.* 2005;95:948–54.
14. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, Abraham WT, et al. Relationship between obesity and B-type natriuretic peptide levels. *Arch Intern Med.* 2004;164:2247–52.
15. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides results from the Dallas Heart Study. *Circulation.* 2005;112:2163–8.
16. Changchien EM, Ahmed S, Betti F, Higa J, Kiely K, Hernandez-Boussard T, et al. B-type natriuretic peptide increases after gastric bypass surgery and correlates with weight loss. *Surg Endosc.* 2011;25:2338–43.

17. Chen-Tournoux A, Khan AM, Baggish AL, Castro VM, Semigran MJ, McCabe EL, et al. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. *Am J Cardiol*. 2010;106:1450–5.
18. Kistorp C, Bliddal H, Goetze JP, Christensen R, Faber J. Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. *BMC Obes*. 2014;1:1–9.
19. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. *J Hypertens*. 1997;15:1695–8.
20. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). *Eur J Heart Fail*. 2013;15:1062–73.
21. Haufe S, Kaminski J, Utz W, Haas V, Mähler A, Daniels MA, et al. Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. *J Hypertens*. 2015;33:1458–64.
22. Bordinchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. *J Clin Invest*. 2012;122:1022–36.
23. Belegoli A, Diniz M, Nunes M, Barbosa M, Fernandes S, Abreu M, et al. Reduced brain natriuretic peptide levels in class III obesity: the role of metabolic and cardiovascular factors. *Obes Facts*. 2011;4:427–32.
24. Woodard GE, Rosado JA. Natriuretic peptides in vascular physiology and pathology. *Int Rev Cell Mol Biol*. 2008;268:59–93.
25. Moro C. Natriuretic peptides and fat metabolism. *Curr Opin Clin Nutr Metab Care*. 2013;16:645–9.
26. Moro C, Smith SR. Natriuretic peptides: new players in energy homeostasis. *Diabetes*. 2009;58:2726–8.
27. Sengenès C, Berlan M, De Glisèzinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. *FASEB J*. 2000;14:1345–51.
28. Engeli S, Birkenfeld AL, Badin P-M, Bourlier V, Louche K, Viguier N, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. *J Clin Investig*. 2012;122:4675.
29. Hulks G, Jardine A, Connell J, Thomson N. Bronchodilator effect of atrial natriuretic peptide in asthma. *BMJ*. 1989;299:1081–2.
30. Hernandez TL, Ballard RD, Weil KM, Shepard TY, Scherzinger AL, Stamm ER, et al. Effects of maintained weight loss on sleep dynamics and neck morphology in severely obese adults. *Obesity*. 2009;17:84–91.
31. Gabrielsen AM, Lund MB, Kongerud J, Viken KE, Røislien J, Hjelmæsæth J, et al. Pulmonary function and blood gases after gastric bypass and lifestyle intervention: a comparative study. *Clin Obes*. 2013;3:117–23.
32. Hofsø D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. *Eur J Endocrinol*. 2010;163:735–45.
33. Nordstrand N, Hertel JK, Hofsø D, Sandbu R, Saltvedt E, Røislien J, et al. A controlled clinical trial of the effect of gastric bypass surgery and intensive lifestyle intervention on nocturnal hypertension and the circadian blood pressure rhythm in patients with morbid obesity. *Surgery*. 2012;151:674–80.
34. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2007;176:532–55.
35. Iber C, Ancoli-Israel S, Chesson A, Quan S, authors for the American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. 2007.
36. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26:319–38.
37. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J*. 2005;26:720–35.
38. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. *Eur Respir J*. 2005;26:511–22.
39. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J*. 1993;16:55–40.
40. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. *Obesity*. 2012;20:1511–8.
41. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. *J Am Soc Nephrol*. 2001;12:1211–7.
42. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR. Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. *Clin Chem*. 2007;53:1928–35.
43. Grayburn RL, Kaka Y, Tang WH. Contemporary insights and novel treatment approaches to central sleep apnea syndrome in heart failure. *Curr Treat Options Cardiovasc Med*. 2014;16:322.
44. Lyons OD, Bradley TD. Heart failure and sleep apnea. *Can J Cardiol*. 2013;31:898–908.
45. Roca GQ, Redline S, Punjabi N, Claggett B, Ballantyne CM, Solomon SD, et al. Sleep apnea is associated with subclinical myocardial injury in the community: the ARIC-SHHS study. *Am J Respir Crit Care Med*. 2013;188:1460–5.
46. Ljunggren M, Lindahl B, Theorell-Haglow J, Lindberg E. Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women. *Sleep*. 2012;35:1521–7.
47. Kita H, Ohi M, Chin K, Noguchi T, Otsuka N, Tsuboi T, et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. *J Sleep Res*. 1998;7:199–207.
48. Gottlieb JD, Schwartz AR, Marshall J, Ouyang P, Kern L, Shetty V, et al. Hypoxia, not the frequency of sleep apnea, induces acute hemodynamic stress in patients with chronic heart failure. *J Am Coll Cardiol*. 2009;54:1706–12.
49. Svatikova A, Shamsuzzaman AS, Wolk R, Phillips BG, Olson LJ, Somers VK. Plasma brain natriuretic peptide in obstructive sleep apnea. *Am J Cardiol*. 2004;94:529–32.
50. Nowatzke WL, Cole TG. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for 1 year and after multiple freeze-thaw cycles. *Clin Chem*. 2003;49:1560–2.
51. Cauliez B, Guignery J, Marinier S, Mariau I, Lavoine A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. *Ann Clin Biochem*. 2008;45:318–9.
52. Sabe MA, Jacob MS, Taylor DO. A new class of drugs for systolic heart failure: the PARADIGM-HF study. *Cleve Clin J Med*. 2015;82:693–701.
53. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371:993–1004.